Tag: Roche’s Tecentriq-chemotherapy combo against lung cancer wins FDA approval

Roche’s Tecentriq-chemotherapy combo against lung cancer wins FDA approval

December 12, 2019

Swiss drugmaker Roche’s new immunotherapy solution, Tecentriq, has received the US Food and Drug Administration’s (FDA) approval for use along with Celgene’s Abraxane and carboplatin chemotherapy to treat metastatic non-squamous non-small cell lung cancer (NSCLC), with no EGFR or ALK mutations. A recent study on Tecentriq showed the immuno-chemotherapy combo could extend patients’ lives by […]

Continue Reading